As explained elsewhere, bioprospecting is the search for new
chemicals in living things that will have
some medical or commercial use. And
while it is a high risk area for stakeholders,
it can have massive returns. In the 1990s,
of the 25 top-selling pharmaceuticals,
10 were originally sourced from animals,
plants or micro-organisms. Since 2000,
these have accounted for tens of billions of dollars in global sales.
| Legal Statement -Terms of Use Contact Webmaster Copyright 2012. DeoBioSciences, Inc. All rights reserved. |
Site Word Search
Risk is an inherent part of the entire life sciences/biotech industry. Across, the industry, which includes some of the world's greatest brands, on average, fewer than 20% of all experimental drugs that enter human clinical trials yields a marketable product. The percentage of funded research projects that ultimately succeed is even smaller. On top of that, we've seen that some companies violate ethical standards, even to the detriment of their stake holders. Nevertheless, we believe that biotechnology and research missions like ours are full of promise and excitement. Feel free to check out some news articles that show why this sector is so interesting and rewarding. |
 | |  | |  | |  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Disclaimer
When used in this website, the words "intends," "believes," "anticipates","plans"
and "expects" and similar expressions are intended to identify forward-looking
statements. Such statements are subject to risks and uncertainties which could
cause actual results to differ materially from those projected. Factors that could
cause or contribute to such differences include an inability to duplicate the results
demonstrated in clinical studies, timely development of any potential products
that can be shown to be safe and effective, the inability to raise the necessary
financing for the company, receiving necessary regulatory approvals, difficulties in
manufacturing any of the Company's potential products and the risk factors set
forth from time to time in DeoBioSciences, Inc.'s SEC filings. The Company
undertakes no obligation to publicly release the result of any revision to these
forward-looking statements which may be made to reflect the events or
circumstances after the date thereof or to reflect the occurrence of unanticipated
events.
When used in this website, the words "intends," "believes," "anticipates","plans"
and "expects" and similar expressions are intended to identify forward-looking
statements. Such statements are subject to risks and uncertainties which could
cause actual results to differ materially from those projected. Factors that could
cause or contribute to such differences include an inability to duplicate the results
demonstrated in clinical studies, timely development of any potential products
that can be shown to be safe and effective, the inability to raise the necessary
financing for the company, receiving necessary regulatory approvals, difficulties in
manufacturing any of the Company's potential products and the risk factors set
forth from time to time in DeoBioSciences, Inc.'s SEC filings. The Company
undertakes no obligation to publicly release the result of any revision to these
forward-looking statements which may be made to reflect the events or
circumstances after the date thereof or to reflect the occurrence of unanticipated
events.
| Biotech News |
 |
